These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 13697901)

  • 21. Iron storage disease in parents and sibs of infants with neonatal hemochromatosis: 30-year follow-up.
    Dalhøj J; Kiaer H; Wiggers P; Grady RW; Jones RL; Knisely AS
    Am J Med Genet; 1990 Nov; 37(3):342-5. PubMed ID: 2260562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Chelating agents of the edathamil calcium type during ionic overload (iron & lead)].
    LAMACHE A; BOUREL M; CORMIER M; AZARD C; LENOIR P
    Therapie; 1958; 13(2):282-95. PubMed ID: 13556709
    [No Abstract]   [Full Text] [Related]  

  • 23. [Comparative studies on the efficacy of chelating agents in experimental iron storage disease in the rat].
    Bohne F; Harmuth-Hoene AE; Weber KM
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1967; 257(4):409-19. PubMed ID: 4232727
    [No Abstract]   [Full Text] [Related]  

  • 24. [Therapeutic & diagnostic import of siderinuria due to chelating agents in hemochromatosis].
    GIRARD M; CREYSSEL R; PANSU C; BEL A; GOLHEN A
    J Med Lyon; 1958 Jan; 39(913):87-94. PubMed ID: 13514366
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of tannic acid on iron absorption in straw-colored fruit bats (Eidolon helvum).
    Lavin SR; Chen Z; Abrams SA
    Zoo Biol; 2010; 29(3):335-43. PubMed ID: 19598244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The treatment of hemochromatosis with the new iron chelating agent (desferrioxamine)].
    CONTE M; BODIN F; DUHAMEL
    Bull Mem Soc Med Hop Paris; 1963 Apr 19-26; 114():533-8. PubMed ID: 14022705
    [No Abstract]   [Full Text] [Related]  

  • 27. [Present aspects of the treatment of hemochromatosis (apropos of 100 observations)].
    Darnis F; Mossé A; Breauté C; Delorme ML
    Ann Med Interne (Paris); 1971 Dec; 122(12):1193-210. PubMed ID: 5151624
    [No Abstract]   [Full Text] [Related]  

  • 28. A unique rodent model for both the cardiotoxic and hepatotoxic effects of prolonged iron overload.
    Carthew P; Dorman BM; Edwards RE; Francis JE; Smith AG
    Lab Invest; 1993 Aug; 69(2):217-22. PubMed ID: 7688836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gastric absorption of iron.
    Dagg JH; Kuhn IN; Templeton FE; Finch CA
    Gastroenterology; 1967 Dec; 53(6):918-22. PubMed ID: 4383630
    [No Abstract]   [Full Text] [Related]  

  • 30. [Specific treatment of excessive iron deposition in the tissues].
    Plachecka-Gutowska M; Mikolajew M
    Pol Arch Med Wewn; 1965; 35(1):111-7. PubMed ID: 5900073
    [No Abstract]   [Full Text] [Related]  

  • 31. Distribution of storage iron as body stores expand in patients with hemochromatosis.
    Valberg LS; Simon JB; Manley PN; Corbett WE; Ludwig J
    J Lab Clin Med; 1975 Sep; 86(3):479-89. PubMed ID: 1151163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on iron metabolism and molecular perspective of common genetic and acquired disorder, hemochromatosis.
    Yun S; Vincelette ND
    Crit Rev Oncol Hematol; 2015 Jul; 95(1):12-25. PubMed ID: 25737209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthetic chelating agents in iron metabolism.
    CLETON F; TURNBULL A; FINCH CA
    J Clin Invest; 1963 Mar; 42(3):327-37. PubMed ID: 14021718
    [No Abstract]   [Full Text] [Related]  

  • 34. [Hemochromatosis].
    Kohgo Y; Urushizaki I
    Nihon Rinsho; 1986 Aug; 44(8):1879-91. PubMed ID: 3537377
    [No Abstract]   [Full Text] [Related]  

  • 35. Non-HFE hemochromatosis: pathophysiological and diagnostic aspects.
    Bardou-Jacquet E; Ben Ali Z; Beaumont-Epinette MP; Loreal O; Jouanolle AM; Brissot P
    Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):143-54. PubMed ID: 24321703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis.
    Nick H; Allegrini PR; Fozard L; Junker U; Rojkjaer L; Salie R; Niederkofler V; O'Reilly T
    Exp Biol Med (Maywood); 2009 May; 234(5):492-503. PubMed ID: 19234060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of synthetic chelating agents on iron metabolism].
    FINCH CA
    Ned Tijdschr Geneeskd; 1963 Feb; 107():320-1. PubMed ID: 13945202
    [No Abstract]   [Full Text] [Related]  

  • 38. [Molecular basis of hereditary hemochromatosis].
    Romanowski T; Sikorska K; Bielawski KP
    Postepy Hig Med Dosw (Online); 2006; 60():217-26. PubMed ID: 16641891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Storage iron regulation.
    Hershko C
    Prog Hematol; 1977; 10():105-48. PubMed ID: 337357
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical usefulness of iron chelating agents.
    Waxman HS; Brown EB
    Prog Hematol; 1969; 6():338-73. PubMed ID: 4976246
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.